Is apidra a biosimilar insulin?

No. Apidra is the brand name for insulin glulisine, a rapid-acting insulin analog developed by Sanofi. It is not a biosimilar.

Biosimilar insulins do exist for some other insulins (for example, lispro and glargine products), but there isn’t a widely used biosimilar version of insulin glulisine (Apidra) itself. If you have questions about choosing between insulins, a clinician can help.